Literature DB >> 20842183

How does diabetes accelerate Alzheimer disease pathology?

Catrina Sims-Robinson1, Bhumsoo Kim, Andrew Rosko, Eva L Feldman.   

Abstract

Diabetes and Alzheimer disease (AD)-two age-related diseases-are both increasing in prevalence, and numerous studies have demonstrated that patients with diabetes have an increased risk of developing AD compared with healthy individuals. The underlying biological mechanisms that link the development of diabetes with AD are not fully understood. Abnormal protein processing, abnormalities in insulin signaling, dysregulated glucose metabolism, oxidative stress, the formation of advanced glycation end products, and the activation of inflammatory pathways are features common to both diseases. Hypercholesterolemia is another factor that has received attention, owing to its potential association with diabetes and AD. This Review summarizes the mechanistic pathways that might link diabetes and AD. An understanding of this complex interaction is necessary for the development of novel drug therapies and lifestyle guidelines aimed at the treatment and/or prevention of these diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20842183      PMCID: PMC3199576          DOI: 10.1038/nrneurol.2010.130

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  144 in total

1.  Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons.

Authors:  M Lesort; G V Johnson
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

2.  p38 kinase is activated in the Alzheimer's disease brain.

Authors:  K Hensley; R A Floyd; N Y Zheng; R Nael; K A Robinson; X Nguyen; Q N Pye; C A Stewart; J Geddes; W R Markesbery; E Patel; G V Johnson; G Bing
Journal:  J Neurochem       Date:  1999-05       Impact factor: 5.372

3.  Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. A retrospective postmortem immunocytochemical and histofluorescent study.

Authors:  J Heitner; D Dickson
Journal:  Neurology       Date:  1997-11       Impact factor: 9.910

4.  Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats.

Authors:  Miroslava Hrnkova; Norbert Zilka; Zuzana Minichova; Peter Koson; Michal Novak
Journal:  Brain Res       Date:  2006-12-13       Impact factor: 3.252

5.  Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis.

Authors:  S Hoyer
Journal:  J Neural Transm (Vienna)       Date:  1998       Impact factor: 3.575

6.  Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging.

Authors:  Chris MacKnight; Kenneth Rockwood; Erin Awalt; Ian McDowell
Journal:  Dement Geriatr Cogn Disord       Date:  2002       Impact factor: 2.959

7.  N epsilon-carboxymethyllysine in brain aging, diabetes mellitus, and Alzheimer's disease.

Authors:  Xavier Gironès; Arantxa Guimerà; Celia-Z Cruz-Sánchez; Arantxa Ortega; Noboyuki Sasaki; Zenji Makita; José Vivente Lafuente; Raj Kalaria; Félix F Cruz-Sánchez
Journal:  Free Radic Biol Med       Date:  2004-05-15       Impact factor: 7.376

8.  Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment.

Authors:  G J Biessels; A Kamal; I J Urban; B M Spruijt; D W Erkelens; W H Gispen
Journal:  Brain Res       Date:  1998-07-27       Impact factor: 3.252

9.  Cholesterol accumulation and diabetes in pancreatic beta-cell-specific SREBP-2 transgenic mice: a new model for lipotoxicity.

Authors:  Mayumi Ishikawa; Yuko Iwasaki; Shigeru Yatoh; Toyonori Kato; Shin Kumadaki; Noriyuki Inoue; Takashi Yamamoto; Takashi Matsuzaka; Yoshimi Nakagawa; Naoya Yahagi; Kazuto Kobayashi; Akimitsu Takahashi; Nobuhiro Yamada; Hitoshi Shimano
Journal:  J Lipid Res       Date:  2008-08-05       Impact factor: 5.922

10.  GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides.

Authors:  Christopher J Phiel; Christina A Wilson; Virginia M-Y Lee; Peter S Klein
Journal:  Nature       Date:  2003-05-22       Impact factor: 49.962

View more
  147 in total

Review 1.  The role of phytochemicals in the treatment and prevention of dementia.

Authors:  Melanie-Jayne R Howes; Elaine Perry
Journal:  Drugs Aging       Date:  2011-06-01       Impact factor: 3.923

2.  Intracerebroventricular streptozotocin exacerbates Alzheimer-like changes of 3xTg-AD mice.

Authors:  Yanxing Chen; Zhihou Liang; Zhu Tian; Julie Blanchard; Chun-Ling Dai; Sonia Chalbot; Khalid Iqbal; Fei Liu; Cheng-Xin Gong
Journal:  Mol Neurobiol       Date:  2013-08-31       Impact factor: 5.590

Review 3.  Type 2 diabetes and cognitive impairment: contributions from neuroimaging.

Authors:  John P Ryan; David F Fine; Caterina Rosano
Journal:  J Geriatr Psychiatry Neurol       Date:  2014-01-05       Impact factor: 2.680

Review 4.  Mitophagy and Alzheimer's Disease: Cellular and Molecular Mechanisms.

Authors:  Jesse S Kerr; Bryan A Adriaanse; Nigel H Greig; Mark P Mattson; M Zameel Cader; Vilhelm A Bohr; Evandro F Fang
Journal:  Trends Neurosci       Date:  2017-02-09       Impact factor: 13.837

5.  Cognitive function and fine motor speed in older women with diabetes mellitus: results from the women's health initiative study of cognitive aging.

Authors:  Mark A Espeland; Michael E Miller; Joseph S Goveas; Patricia E Hogan; Laura H Coker; Jeff Williamson; Michelle Naughton; Susan M Resnick
Journal:  J Womens Health (Larchmt)       Date:  2011-08-05       Impact factor: 2.681

Review 6.  Misfolded proteins in Alzheimer's disease and type II diabetes.

Authors:  Alaina S DeToma; Samer Salamekh; Ayyalusamy Ramamoorthy; Mi Hee Lim
Journal:  Chem Soc Rev       Date:  2011-08-04       Impact factor: 54.564

Review 7.  New views and possibilities of antidiabetic drugs in treating and/or preventing mild cognitive impairment and Alzheimer's Disease.

Authors:  Kai Long Zhong; Fang Chen; Hao Hong; Xuan Ke; Yang Ge Lv; Su Su Tang; Yu Bing Zhu
Journal:  Metab Brain Dis       Date:  2018-04-06       Impact factor: 3.584

8.  Genetically reducing mTOR signaling rescues central insulin dysregulation in a mouse model of Alzheimer's disease.

Authors:  Antonella Caccamo; Ramona Belfiore; Salvatore Oddo
Journal:  Neurobiol Aging       Date:  2018-04-05       Impact factor: 4.673

9.  The relationship between fasting serum glucose and cerebral glucose metabolism in late-life depression and normal aging.

Authors:  Christopher M Marano; Clifford I Workman; Christopher H Lyman; Elisse Kramer; Carol R Hermann; Yilong Ma; Vijay Dhawan; Thomas Chaly; David Eidelberg; Gwenn S Smith
Journal:  Psychiatry Res       Date:  2014-02-01       Impact factor: 3.222

10.  Pioglitazone ameliorates memory deficits in streptozotocin-induced diabetic mice by reducing brain β-amyloid through PPARγ activation.

Authors:  Li-ping Liu; Tian-hua Yan; Li-ying Jiang; Wei Hu; Meng Hu; Chao Wang; Qian Zhang; Yan Long; Jiang-qing Wang; Yong-qi Li; Mei Hu; Hao Hong
Journal:  Acta Pharmacol Sin       Date:  2013-03-25       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.